Beverly Moy Selected Research

Disease Progression

1/2023	A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
12/2021	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
3/2021	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
11/2020	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.
1/2020	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
3/2016	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Beverly Moy Research Topics

Disease

87	Breast Neoplasms (Breast Cancer) 05/2024 - 11/2005
46	Neoplasms (Cancer) 05/2024 - 11/2005
9	Brain Neoplasms (Brain Tumor) 04/2023 - 11/2006
6	Disease Progression 01/2023 - 03/2016
6	Circulating Neoplastic Cells 01/2023 - 04/2013
4	Triple Negative Breast Neoplasms 05/2024 - 10/2021
4	Pathologic Complete Response 12/2022 - 10/2017
4	Diarrhea 01/2020 - 07/2007
3	Fatigue 06/2022 - 01/2017
3	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2020
3	Exanthema (Rash) 04/2015 - 07/2007
2	Meningeal Carcinomatosis 08/2020 - 01/2020
2	Central Nervous System Diseases (CNS Diseases) 01/2020 - 03/2016
2	Neurologic Manifestations (Neurological Manifestations) 01/2019 - 03/2016
2	Pain (Aches) 12/2017 - 04/2015
2	Nausea 12/2017 - 03/2016
2	Vomiting 12/2017 - 03/2016
2	Cardiotoxicity 05/2011 - 07/2007
1	Alopecia (Baldness) 01/2023
1	Secretory breast carcinoma 01/2023
1	Hypersensitivity (Allergy) 01/2023
1	Rupture 08/2022
1	Chorioamnionitis 08/2022
1	Premature Birth (Birth, Premature) 08/2022
1	Microsatellite Instability 01/2022
1	Death (Near-Death Experience) 01/2022
1	Breakthrough Infections 01/2022

Drug/Important Bio-Agent (IBA)

22	Hormones (Hormone)IBA 01/2023 - 08/2006
19	Trastuzumab (Herceptin)FDA Link 01/2023 - 12/2009
14	human ERBB2 proteinIBA 01/2023 - 06/2010
12	neratinibIBA 01/2023 - 03/2016
12	Biomarkers (Surrogate Marker)IBA 01/2023 - 11/2006
12	Lapatinib (GW572016)FDA Link 11/2021 - 11/2006
10	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 11/2005
10	ErbB Receptors (EGF Receptor)IBA 01/2023 - 10/2014
6	Tyrosine Kinase InhibitorsIBA 01/2023 - 04/2014
6	Estrogen ReceptorsIBA 10/2020 - 10/2014
5	Capecitabine (Xeloda)FDA Link 12/2021 - 01/2019
4	Immunoconjugates (Immunoconjugate)IBA 05/2024 - 10/2021
4	Cell-Free Nucleic AcidsIBA 04/2023 - 01/2020
4	APTIBA 01/2023 - 06/2015
4	pembrolizumabIBA 01/2023 - 01/2020
3	sacituzumab govitecanIBA 05/2024 - 10/2021
3	Circulating Tumor DNAIBA 10/2023 - 11/2020
3	abemaciclibIBA 01/2023 - 01/2017
3	Cyclin-Dependent Kinase 4IBA 01/2023 - 01/2017
3	palbociclibIBA 01/2023 - 01/2017
3	Diphosphonates (Bisphosphonates)IBA 12/2022 - 06/2017
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2021 - 01/2017
3	Phenobarbital (Luminal)FDA Link 01/2019 - 10/2012
3	Aromatase InhibitorsIBA 01/2017 - 04/2014
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2024 - 01/2020
2	Denosumab FDA Link 12/2022 - 01/2022
2	Fulvestrant (Faslodex)FDA Link 01/2022 - 11/2019
2	Zoledronic Acid (Zometa)FDA Link 01/2022 - 06/2017
2	Clodronic Acid (Clodronate)IBA 01/2022 - 06/2017
2	AlpelisibIBA 01/2022 - 11/2019
2	AnthracyclinesIBA 12/2021 - 05/2011
2	taxaneIBA 12/2021 - 08/2021
2	AntigensIBA 10/2021 - 11/2020
2	ribociclibIBA 08/2021 - 01/2017
2	Loperamide (Imodium)FDA LinkGeneric 01/2020 - 03/2016
2	N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)IBA 12/2018 - 12/2009
2	Hemoglobins (Hemoglobin)IBA 02/2017 - 01/2013
2	exemestane (Aromasin)FDA Link 01/2017 - 04/2014
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2016 - 11/2005
2	bosutinibIBA 04/2014 - 04/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2011 - 06/2010
2	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2011 - 06/2010
1	talazoparibIBA 05/2024
1	B7-H1 AntigenIBA 01/2023
1	larotrectinibIBA 01/2023
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2023
1	entrectinibIBA 01/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 08/2022
1	Taxoids (Taxanes)IBA 08/2022
1	Ibandronic Acid (Boniva)FDA Link 01/2022
1	AntibodiesIBA 01/2022
1	hydroxide ionIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	VaccinesIBA 01/2022
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2022
1	dostarlimabIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2021
1	Monoclonal AntibodiesIBA 10/2021
1	Surface Antigens (Surface Antigen)IBA 10/2021

Therapy/Procedure

50	Therapeutics 05/2024 - 08/2006
29	Drug Therapy (Chemotherapy) 04/2024 - 11/2005
12	Adjuvant Chemotherapy 11/2023 - 11/2005
5	Neoadjuvant Therapy 12/2022 - 01/2013
4	Radiotherapy 01/2021 - 11/2013
4	Mastectomy (Mammectomy) 08/2020 - 01/2012
2	Drug Tapering 10/2023 - 06/2010
2	Aftercare (After-Treatment) 01/2023 - 08/2022
1	Precision Medicine 11/2023
1	Immunotherapy 01/2023
1	Terminal Care (Care, Terminal) 01/2022
1	Palliative Care (Palliative Therapy) 01/2022